News

A new wearable adaptive refractor (VisionFit; Adaptica, Padova, Italy) for subjective refraction combines the features of trial frames and manual and automated phoropters. With this mobile device, patients can be examined while sitting or standing, and the unit itself can be easily transported.

An anterior segment diagnostic imaging platform based on high-speed swept-source OCT is being developed by Heidelberg Engineering. It will provide biometry as well as corneal topography and tomography, while also enabling visualization of the anterior and posterior lens surfaces and assessment of the anterior chamber angle.

Robert Dempsey, vice president and business unit head at Shire Pharmaceutical’s Ophthalmics Business Unit, recently talked with Ophthalmology Times Group Content Director Mark L. Dlugoss about Shire’s entry into the eye care market. Among the topics discussed are Shire’s attraction to the market, Lifitegrast–its potential dry eye drug, and other potential ophthalmic compounds.

Bruce Allan, MD, UK and David Kang, MD, South Korea, are SCHWIND users for many years. Both greatly appreciate the outstanding performance features offered by the SCHWIND AMARIS excimer laser technology. The company‘s spirit of innovation, their willingness to advance the art and science of refractive surgery, and their responsiveness to feedback. In this video, Dr. Allan and Dr. Kang comment on the sophisticated SCHWIND AMARIS features SmartPulse Technology and TransPRK.

Professor Rudy Nuijts, Professor James Wolffsohn, Dr Mark Cherny and Dr David Frazer share their views on the taboo topic of refractive surprise in cataract surgery. They explain what it means to have a refractive surprise, why they occur, the importance of patient satisfaction and the options available to surgeons (including Rayner Sulcoflex® case studies) when a situation involving a refractive surprise arises.

Professor Marc De Smet talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.

Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.

Contact lens-Assisted corneal crosslinking (CA-CXL) is a novel technique in which a riboflavin-soaked ultraviolet (UV) barrier-free soft contact lens is applied over the denuded cornea prior to UVA irradiation. It is used to allow CXL in eyes with a thin cornea and has been associated with good results, and can be done with a standard or accelerated CXL protocol.

Patients treated with Omidria (phenylephrine and ketorolac injection 1%/0.3%, Omeros) reported significantly less early postoperative pain following cataract surgery or IOL exchange than patients treated with placebo and also had significantly lower analgesic use. These findings suggest that use of Omidria could help improve patient satisfaction with these procedures.